Cargando…

Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization

The preparation of amorphous and co-amorphous systems (CAMs) effectively addresses the solubility and bioavailability issues of poorly water-soluble chemical entities. However, stress conditions imposed during common pharmaceutical processing (e.g., tableting) may cause the recrystallization of the...

Descripción completa

Detalles Bibliográficos
Autores principales: da Costa, Nuno F., Daniels, Rolf, Fernandes, Ana I., Pinto, João F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499418/
https://www.ncbi.nlm.nih.gov/pubmed/36142179
http://dx.doi.org/10.3390/ijms231810234
_version_ 1784794988272418816
author da Costa, Nuno F.
Daniels, Rolf
Fernandes, Ana I.
Pinto, João F.
author_facet da Costa, Nuno F.
Daniels, Rolf
Fernandes, Ana I.
Pinto, João F.
author_sort da Costa, Nuno F.
collection PubMed
description The preparation of amorphous and co-amorphous systems (CAMs) effectively addresses the solubility and bioavailability issues of poorly water-soluble chemical entities. However, stress conditions imposed during common pharmaceutical processing (e.g., tableting) may cause the recrystallization of the systems, warranting close stability monitoring throughout production. This work aimed at assessing the water and heat stability of amorphous olanzapine (OLZ) and OLZ-CAMs when subject to wet granulation and pelletization. Starting materials and products were characterized using calorimetry, diffractometry and spectroscopy, and their performance behavior was evaluated by dissolution testing. The results indicated that amorphous OLZ was reconverted back to a crystalline state after exposure to water and heat; conversely, OLZ-CAMs stabilized with saccharin (SAC), a sulfonic acid, did not show any significant loss of the amorphous content, confirming the higher stability of OLZ in the CAM. Besides resistance under the processing conditions of the dosage forms considered, OLZ-CAMs presented a higher solubility and dissolution rate than the respective crystalline counterpart. Furthermore, in situ co-amorphization of OLZ and SAC during granule production with high fractions of water unveils the possibility of reducing production steps and associated costs.
format Online
Article
Text
id pubmed-9499418
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94994182022-09-23 Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization da Costa, Nuno F. Daniels, Rolf Fernandes, Ana I. Pinto, João F. Int J Mol Sci Article The preparation of amorphous and co-amorphous systems (CAMs) effectively addresses the solubility and bioavailability issues of poorly water-soluble chemical entities. However, stress conditions imposed during common pharmaceutical processing (e.g., tableting) may cause the recrystallization of the systems, warranting close stability monitoring throughout production. This work aimed at assessing the water and heat stability of amorphous olanzapine (OLZ) and OLZ-CAMs when subject to wet granulation and pelletization. Starting materials and products were characterized using calorimetry, diffractometry and spectroscopy, and their performance behavior was evaluated by dissolution testing. The results indicated that amorphous OLZ was reconverted back to a crystalline state after exposure to water and heat; conversely, OLZ-CAMs stabilized with saccharin (SAC), a sulfonic acid, did not show any significant loss of the amorphous content, confirming the higher stability of OLZ in the CAM. Besides resistance under the processing conditions of the dosage forms considered, OLZ-CAMs presented a higher solubility and dissolution rate than the respective crystalline counterpart. Furthermore, in situ co-amorphization of OLZ and SAC during granule production with high fractions of water unveils the possibility of reducing production steps and associated costs. MDPI 2022-09-06 /pmc/articles/PMC9499418/ /pubmed/36142179 http://dx.doi.org/10.3390/ijms231810234 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
da Costa, Nuno F.
Daniels, Rolf
Fernandes, Ana I.
Pinto, João F.
Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization
title Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization
title_full Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization
title_fullStr Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization
title_full_unstemmed Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization
title_short Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization
title_sort amorphous and co-amorphous olanzapine stability in formulations intended for wet granulation and pelletization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499418/
https://www.ncbi.nlm.nih.gov/pubmed/36142179
http://dx.doi.org/10.3390/ijms231810234
work_keys_str_mv AT dacostanunof amorphousandcoamorphousolanzapinestabilityinformulationsintendedforwetgranulationandpelletization
AT danielsrolf amorphousandcoamorphousolanzapinestabilityinformulationsintendedforwetgranulationandpelletization
AT fernandesanai amorphousandcoamorphousolanzapinestabilityinformulationsintendedforwetgranulationandpelletization
AT pintojoaof amorphousandcoamorphousolanzapinestabilityinformulationsintendedforwetgranulationandpelletization